Advertisement

Comment on: “Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study”

Published:October 18, 2022DOI:https://doi.org/10.1016/j.dld.2022.09.014
      Dear Editor,
      We would like to comment on the article, entitled “Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study [
      • Macaluso F.S.
      • Principi M.
      • Facciotti F.
      • Contaldo A.
      • Todeschini A.
      • Saibeni S.
      • Bezzio C.
      • Castiglione F.
      • Nardone O.M.
      • Spagnuolo R.
      • Fantini M.C.
      • Riguccio G.
      • Caprioli F.
      • Viganò C.
      • Felice C.
      • Fiorino G.
      • Correale C.
      • Bodini G.
      • Milla M.
      • Scardino G.
      • Vernero M.
      • Desideri F.
      • Mannino M.
      • Rizzo G.
      • Orlando A.
      Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: data from ESCAPE-IBD, an IG-IBD study.
      ]." Although the majority of IBD patients exhibited seropositivity following COVID-19 vaccinations, Macaluso et al. found that the size of the humoral response was much lower than in HCs [
      • Macaluso F.S.
      • Principi M.
      • Facciotti F.
      • Contaldo A.
      • Todeschini A.
      • Saibeni S.
      • Bezzio C.
      • Castiglione F.
      • Nardone O.M.
      • Spagnuolo R.
      • Fantini M.C.
      • Riguccio G.
      • Caprioli F.
      • Viganò C.
      • Felice C.
      • Fiorino G.
      • Correale C.
      • Bodini G.
      • Milla M.
      • Scardino G.
      • Vernero M.
      • Desideri F.
      • Mannino M.
      • Rizzo G.
      • Orlando A.
      Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: data from ESCAPE-IBD, an IG-IBD study.
      ]. These results appear to be mostly unrelated to the use of immune-modifying therapies, in contrast to those of other research [
      • Macaluso F.S.
      • Principi M.
      • Facciotti F.
      • Contaldo A.
      • Todeschini A.
      • Saibeni S.
      • Bezzio C.
      • Castiglione F.
      • Nardone O.M.
      • Spagnuolo R.
      • Fantini M.C.
      • Riguccio G.
      • Caprioli F.
      • Viganò C.
      • Felice C.
      • Fiorino G.
      • Correale C.
      • Bodini G.
      • Milla M.
      • Scardino G.
      • Vernero M.
      • Desideri F.
      • Mannino M.
      • Rizzo G.
      • Orlando A.
      Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: data from ESCAPE-IBD, an IG-IBD study.
      ]. Numerous variables could have a substantial impact on the COVID-19 vaccination's efficacy. Different doses and administration techniques are available. Compared to a typical, healthy vaccine recipient, patients who use prescription medicines or have underlying medical conditions may be more susceptible to immunizations. We can all agree that it is a good idea to administer the COVID-19 vaccine. The relatively common precursor COVID-19 without symptoms might possibly play a role [
      • Joob B.
      • Wiwanitkit V.
      Letter to the Editor: coronavirus Disease 2019 (COVID-19), Infectivity, and the Incubation Period.
      ].
      Testing is frequently skipped to rule out a prior, asymptomatic COVID-19 infection. Regular blood testing can reveal more about a person's underlying immunological issues. It is possible to more precisely forecast how the COVID-19 vaccination will perform by routinely tracking people's underlying immunological disorders. This is an important consideration when determining the efficacy or safety of a vaccination. Despite the fact that there is frequently little information available regarding pre-vaccination immunological or health status, and the possibility of confounding with non-symptomatic SARS-Co-V2 infection cannot be effectively ruled out, numerous studies have demonstrated the efficacy, safety, or clinical significance of the COVID-19 vaccine. Finally, a recent study found a link between vaccine recipients' baseline genetic variation and their immunological response to vaccination [
      • Čiučiulkaitė I.
      • Möhlendick B.
      • Thümmler L.
      • Fisenkci N.
      • Elsner C.
      • Dittmer U.
      • Siffert W.
      • Lindemann M.
      GNB3 c.825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine.
      ]. If additional research is planned, the implications of the genetic polymorphism should be evaluated.

      Declaration of Competing Interest

      None.

      References

        • Macaluso F.S.
        • Principi M.
        • Facciotti F.
        • Contaldo A.
        • Todeschini A.
        • Saibeni S.
        • Bezzio C.
        • Castiglione F.
        • Nardone O.M.
        • Spagnuolo R.
        • Fantini M.C.
        • Riguccio G.
        • Caprioli F.
        • Viganò C.
        • Felice C.
        • Fiorino G.
        • Correale C.
        • Bodini G.
        • Milla M.
        • Scardino G.
        • Vernero M.
        • Desideri F.
        • Mannino M.
        • Rizzo G.
        • Orlando A.
        Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: data from ESCAPE-IBD, an IG-IBD study.
        Dig Liver Dis. 2022; (S1590-8658(22)00656-9)
        • Joob B.
        • Wiwanitkit V.
        Letter to the Editor: coronavirus Disease 2019 (COVID-19), Infectivity, and the Incubation Period.
        J Prev Med Public Health. 2020; 53: 70
        • Čiučiulkaitė I.
        • Möhlendick B.
        • Thümmler L.
        • Fisenkci N.
        • Elsner C.
        • Dittmer U.
        • Siffert W.
        • Lindemann M.
        GNB3 c.825c>T polymorphism influences T-cell but not antibody response following vaccination with the mRNA-1273 vaccine.
        Front Genet. 2022; 13932043

      Linked Article